The Work We Fund

Funded projects
1,250+
Men's Health Partners
20
Countries
20
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Owen Sharp, CEO
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programs
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” 
Craig Martin, Global Director - Mental Health & Suicide Prevention programs
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programs.

Breast & Prostate Cancer Linkage Grant

Movember Funding to Date

AUD 1,250,000

What we seek to achieve

This award will enable Professor Tilley and collaborators to explore an innovative new treatment path for breast and prostate cancer, which has potential to transform the lives of women and men around the world afflicted with breast or prostate cancer.

Country
Australia
Co-funded
National Breast Cancer Foundation: AUD$1,250,000
Implemented by
Movember Foundation and the National Breast Cancer Foundation
Project start date
Oct 217
Project Status
In Progress

About the project

This research project will investigate a new concept for the treatment of breast and prostate cancers: instead of completely blocking the sex hormone receptors by depriving the body of hormones, the team will test whether the receptors can be “reprogrammed” so that they no longer drive cancer growth but instead function as they would in normal breast or prostate tissues. 

Another important aspect of this innovative strategy is that reprogamming of the hormone receptors could be achieved by repurposing existing drugs that are safe and already approved for other medical purposes, which would vastly increase the speed of translating findings from the laboratory to the clinic. 

Professor Tilley will lead an outstanding collaborative team comprising researchers from the University of Adelaide (Drs Luke Selth and Theresa Hickey), Monash University (Prof Gail Risbridger), Garvan Institute of Medical Research (A/Prof Elgene Lim and Prof Susan Clark), and the Cancer Research UK Cambridge Institute (Dr Jason Carroll). 

The team also incorporates expert advisory groups of clinicians, researchers and patient advocates from around the world, including the Dana Farber Cancer Institute, University of Colorado, and University of North Carolina (USA), the University of Liverpool (UK), University of Toronto (Canada), the Netherlands Cancer Institute (Netherlands) and the Institute of Biology and Experimental Medicine (Argentina).

This research is bringing together the best and brightest cancer researchers in Australia and across the globe, and will be invaluable in our joint efforts to accelerate treatment outcomes for people diagnosed with breast or prostate cancer.
This research project underwent a peer review process involving a panel of experts in clinical and translational research across both the breast and prostate cancer field.

>
Page 1 of 23